|
44 |
FDA Seeks Comment on Quality Considerations for Topical Ophthalmic Drug Products Draft Guidance
|
sureAssist |
2024-12-26 |
34 |
|
43 |
FDA addresses use of remote interactive evaluations in post-pandemic era
|
sureAssist |
2024-12-26 |
35 |
|
42 |
FDA guidance calls for testing all alcohol based products for methanol
|
sureAssist |
2024-12-26 |
36 |
|
41 |
Single use Bioreactors gain popularity worldwide
|
sureAssist |
2024-12-26 |
36 |
|
40 |
How much air does a cleanroom need?
|
sureAssist |
2024-12-26 |
37 |
|
39 |
Risk Tool Selection With ICH Q9(R1) In Mind
|
sureAssist |
2024-12-26 |
41 |
|
38 |
FDA issues draft guidance on post-warning letter meetings under GDUFA III
|
sureAssist |
2024-12-26 |
43 |
|
37 |
5 Best Practices For Responding To FDA Form 483 Inspection Observations
|
sureAssist |
2024-12-26 |
39 |
|
36 |
Cleanrooms: solving the mystery of recurring low level contamination
|
sureAssist |
2024-12-26 |
27 |
|
35 |
The possible Impact of Artificial Intelligence on the Role of the Qualified Person
|
sureAssist |
2024-12-26 |
28 |
